CR11749A - Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina - Google Patents

Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina

Info

Publication number
CR11749A
CR11749A CR11749A CR11749A CR11749A CR 11749 A CR11749 A CR 11749A CR 11749 A CR11749 A CR 11749A CR 11749 A CR11749 A CR 11749A CR 11749 A CR11749 A CR 11749A
Authority
CR
Costa Rica
Prior art keywords
relaxin
treatment
disnea
acute cardiac
cardiac insufficiency
Prior art date
Application number
CR11749A
Other languages
English (en)
Inventor
Unemori Elaine
L Teichman Sam
Cotter Gad
R Stewart Dennis
Jo Whitehouse Martha
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of CR11749A publication Critical patent/CR11749A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La descripción pertenece a los métodos para reducir la descompensación a través de la intervención aguda, incluyendo en los sujetos afligidos con insuficiencia cardiaca aguda descompensada. Particularmente, la descripción proporciona métodos para el tratamiento de la descompensación cardiaca aguda, mediante la administración de una cantidad farmacéuticamente efectiva de relaxina
CR11749A 2008-05-16 2010-10-22 Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina CR11749A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
CR11749A true CR11749A (es) 2011-02-11

Family

ID=40834101

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11749A CR11749A (es) 2008-05-16 2010-10-22 Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina

Country Status (30)

Country Link
US (7) US8053411B2 (es)
EP (2) EP2288373B1 (es)
JP (4) JP5651586B2 (es)
CN (3) CN102036679A (es)
AR (1) AR071810A1 (es)
AU (1) AU2009246114B2 (es)
BR (1) BRPI0913011A2 (es)
CA (1) CA2724540C (es)
CR (1) CR11749A (es)
CY (1) CY1116925T1 (es)
DK (1) DK2288373T3 (es)
EA (2) EA201500552A1 (es)
ES (1) ES2546287T3 (es)
GB (2) GB2459983B (es)
HK (1) HK1202054A1 (es)
HR (1) HRP20150845T1 (es)
HU (1) HUE025483T2 (es)
IL (3) IL208992A (es)
MA (1) MA32389B1 (es)
MX (1) MX2010012450A (es)
MY (2) MY159803A (es)
NZ (3) NZ589009A (es)
PL (1) PL2288373T3 (es)
PT (1) PT2288373E (es)
SG (2) SG10201609580YA (es)
SI (1) SI2288373T1 (es)
TW (1) TWI386202B (es)
UA (1) UA99953C2 (es)
WO (1) WO2009140659A2 (es)
ZA (1) ZA201007449B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0912559A2 (pt) * 2008-05-16 2015-10-13 Corthera Inc método de tratar insuficiência cardíaca crônica
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
EP2544706B1 (en) 2010-03-10 2015-06-17 The University Of Melbourne Modulating aquaporins with relaxin
US9465039B2 (en) 2010-08-06 2016-10-11 Mycartis Nv Perlecan as a biomarker for renal dysfunction
EA030886B1 (ru) * 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
CA2864100A1 (en) * 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
KR102299073B1 (ko) * 2012-10-26 2021-09-09 치에시 파마슈티시 에스.피.아. 심부전에서 혈압을 조절하고 호흡곤란을 감소시키는 방법
PT2981258T (pt) * 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
MX2016010087A (es) * 2014-02-03 2016-10-07 Novartis Ag Filtros para equipos de infusion.
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
US20170100460A1 (en) * 2014-06-13 2017-04-13 Novartis Ag Use of serelaxin to reduce gdf-15
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
ES3041602T3 (en) 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
JP2025528469A (ja) 2022-08-31 2025-08-28 リラクセラ ファルマツォイティッシュ ゲゼルシャフト エムベーハー ウント コー． カーゲー 免疫抑制薬及び処置方法
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
WO1995000645A2 (en) 1993-06-21 1995-01-05 Genentech, Inc. Process for producing relaxin
US5952296A (en) * 1993-07-27 1999-09-14 Bigazzi; Mario Method of using relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
CA2229479C (en) 1995-08-15 2010-03-30 Connective Therapeutics, Inc. Method of promoting angiogenesis
EP1253929B1 (en) * 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1729817B1 (en) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
TW200800206A (en) 2005-07-11 2008-01-01 Abbott Lab Methods for determining how to treat congestive heart failure
WO2009007848A2 (en) 2007-07-12 2009-01-15 Compugen Ltd. Bioactive peptides and method of using same
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
BRPI0912559A2 (pt) 2008-05-16 2015-10-13 Corthera Inc método de tratar insuficiência cardíaca crônica

Also Published As

Publication number Publication date
PL2288373T3 (pl) 2015-11-30
WO2009140659A2 (en) 2009-11-19
US9205132B2 (en) 2015-12-08
BRPI0913011A2 (pt) 2019-09-03
US20120040903A1 (en) 2012-02-16
US20150320834A1 (en) 2015-11-12
HK1187550A1 (zh) 2014-04-11
MX2010012450A (es) 2011-03-21
CN106177914A (zh) 2016-12-07
CN103212063A (zh) 2013-07-24
JP5875646B2 (ja) 2016-03-02
EP2288373B1 (en) 2015-06-24
JP2015013870A (ja) 2015-01-22
JP2016053040A (ja) 2016-04-14
IL208992A0 (en) 2011-01-31
JP2011520918A (ja) 2011-07-21
US20130116181A1 (en) 2013-05-09
HK1139051A1 (en) 2010-09-10
EP2288373A2 (en) 2011-03-02
EA201500552A1 (ru) 2016-07-29
EA201001771A1 (ru) 2011-06-30
GB0908432D0 (en) 2009-06-24
CA2724540A1 (en) 2009-11-19
WO2009140659A3 (en) 2010-07-22
MY158327A (en) 2016-09-30
US9579363B2 (en) 2017-02-28
AR071810A1 (es) 2010-07-14
SG191587A1 (en) 2013-07-31
HK1202054A1 (en) 2015-09-18
HK1140693A1 (en) 2010-10-22
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
US9066916B2 (en) 2015-06-30
CN102036679A (zh) 2011-04-27
US20130210730A1 (en) 2013-08-15
HK1151229A1 (en) 2012-01-27
AU2009246114A1 (en) 2009-11-19
DK2288373T3 (en) 2015-09-28
SI2288373T1 (sl) 2015-12-31
GB2459983B (en) 2010-04-28
JP5638044B2 (ja) 2014-12-10
UA99953C2 (uk) 2012-10-25
MY159803A (en) 2017-02-15
NZ598709A (en) 2013-09-27
EP2829280A1 (en) 2015-01-28
NZ701038A (en) 2016-01-29
US8053411B2 (en) 2011-11-08
EA022948B1 (ru) 2016-03-31
GB0918132D0 (en) 2009-12-02
GB2462221B (en) 2010-09-01
TW200948353A (en) 2009-12-01
US20170151311A1 (en) 2017-06-01
CY1116925T1 (el) 2017-04-05
US20100048475A1 (en) 2010-02-25
US8415301B2 (en) 2013-04-09
JP5651586B2 (ja) 2015-01-14
IL228244A (en) 2016-10-31
HUE025483T2 (en) 2016-02-29
AU2009246114B2 (en) 2013-01-31
ES2546287T3 (es) 2015-09-22
IL208992A (en) 2013-09-30
GB2459983A (en) 2009-11-18
PT2288373E (pt) 2015-10-19
CA2724540C (en) 2014-07-08
GB2462221A (en) 2010-02-03
TWI386202B (zh) 2013-02-21
HRP20150845T1 (hr) 2015-11-06
US20120040902A1 (en) 2012-02-16
JP2013040174A (ja) 2013-02-28
CN103212063B (zh) 2015-07-22
US8372809B2 (en) 2013-02-12
ZA201007449B (en) 2011-06-29
SG10201609580YA (en) 2016-12-29
IL247351A0 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
CL2011001529A1 (es) Uso de un modulador o agonista de los receptores s1p derivado de 2-amino-propan-1,3-diol o 2-amino-propanol para tratar una enfermedad cronica larga en un sujeto, de manera de conseguir una disminucion diaria en la frecuencia cardiaca de 2 latidos/minutos o menos; y kit que lo comprende.
PA8794401A1 (es) Acidos 6-fenilnicotinicos sustituidos y su uso
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
CY1123900T1 (el) Χρηση toy fk506 για τη θεραπεια της πνευμονικης αρτηριακης υπερτασης
UY33369A (es) Heterociclilbencil-pirazoles sustituidos y su uso
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
UY33453A (es) Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina
CL2009001018A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona.
UY32507A (es) Una dosis de ave5026 para el tratamiento de trombormbolismo venoso en pacientes con deterioro renal severo
CO6300936A2 (es) Procedimiento para revertir la remodelacion cardiaca electrofisiologica de un animal con cardiopatia usando beta-adrenoceptores
ES2578729T3 (es) Agente terapéutico para enfermedades relacionadas con el hígado
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
TN2010000504A1 (en) Treating dyspnea associated with acute heart failure with relaxin
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin
SV2011003915A (es) Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia
MD3987B1 (en) Use of Diosmine for the treatment of advancing hepatic cirrhosis associated with cardiac insufficiency
UA69733U (ru) Способ диагностики диастолической дисфункции левого желудочка у больных с неосложненной гипертонической болезнью